maintain buy increas pt
messag increas estim cabometyx renal cell
carcinoma rcc follow success link across efficaci
endpoint top-line readout includ compel data opdivo cabometyx
rcc os hazard ratio competit regimen includ
keytruda inlyta estim peak us
rcc sale still conserv peak assumpt rcc prev
 peak share increas pt potenti upsid
prostat potenti nda file lung cancer initi readout yet reflect
valuat
page analyst certif import disclosur
valuat valu inc per share previous use dcf base valuat method
valuat includ commerci product cabometyx cometriq well probabilityadjust cash flow deriv compani
 pipelin royalti out-licens program use discount rate termin growth rate appli
termin year postassum gener entri cabozantinib discount termin growth rate gener consist
risk risk rate valuat inc includ regulatori commerci setback potenti emerg
new competitor lower product sale expect
page analyst certif import disclosur
licens contract revenu
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
